-
Mashup Score: 59Mentoring the Next Generation of GU Oncology Leaders - Andrea Apolo - 1 month(s) ago
Zachary Klaassen speaks with Andrea Apolo about co-chairing the inaugural GU Early Thought Leaders Conference. Dr. Apolo explains why such career-focused events are vital, noting that the transition from fellowship to independent faculty represents one of the most challenging career phases. Unlike traditional scientific meetings, this conference focused on personal journeys, practical career…
Source: www.urotoday.comCategories: General Medicine NewsTweet
-
Mashup Score: 58Mentoring the Next Generation of GU Oncology Leaders - Andrea Apolo - 1 month(s) ago
Zachary Klaassen speaks with Andrea Apolo about co-chairing the inaugural GU Early Thought Leaders Conference. Dr. Apolo explains why such career-focused events are vital, noting that the transition from fellowship to independent faculty represents one of the most challenging career phases. Unlike traditional scientific meetings, this conference focused on personal journeys, practical career…
Source: www.urotoday.comCategories: General Medicine NewsTweet-
Had so much fun (see interview https://t.co/j1cfke6UQd ) at the inaugural GU Early Thought Leaders 2025 Conference with @zklaassen where we met many future #GUOncology leaders! @PCFnews @urotoday with outstanding faculty @ERPlimackMD @montypal @ArjunBalarMD @AlanBryce9 @tbivala1 https://t.co/YO0q0fOKkA https://t.co/E8DZigvdex
-
-
Mashup Score: 48
We’ve come together as a team dedicated to Bladder Cancer Research with a shared mission: to raise awareness and support the Bladder Cancer Advocacy Network (BCAN), the nation’s only advocacy organization dedicated to advancing bladder cancer research and providing unwavering support to those affected by this illness. Your contribution to our team isn’t just about financial support; it’s about making a profound impact. Bladder cancer is a significant health concern that affects many lives across the
Source: secure2.convio.netCategories: General Medicine NewsTweet
-
Mashup Score: 77ClinicalTrials.gov - 6 month(s) ago
Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Source: www.clinicaltrials.govCategories: General Medicine News, Hem/OncsTweet-
We have several accruing #ClinicalTrials for patients with #SmallCell #BladderCancer 1. #Lurbi +/- #Avelumab LASER https://t.co/pswVh8eMyT 2. #SG +/- #Atezo SMART https://t.co/dOxmuq6E5i 3. #CaboNivoIpi ICONIC https://t.co/3Aghb8BKZq ncimo_referrals@mail.nih.gov / ☎️240-760-6006 https://t.co/F68KhVHh08
-
-
Mashup Score: 31Google Forms: Sign-in - 6 month(s) ago
Access Google Forms with a personal Google account or Google Workspace account (for business use).
Source: accounts.google.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 100Google Forms: Sign-in - 6 month(s) ago
Access Google Forms with a personal Google account or Google Workspace account (for business use).
Source: accounts.google.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8AI-derived Tumor Volume from Multiparametric MRI and Outcomes in Localized Prostate Cancer | Radiology - 8 month(s) ago
Background An artificial intelligence (AI)–based method for measuring intraprostatic tumor volume based on data from MRI may provide prognostic information. Purpose To evaluate whether the total volume of intraprostatic tumor from AI-generated segmentations (VAI) provides independent prognostic information in patients with localized prostate cancer treated with radiation therapy (RT) or radical prostatectomy (RP). Materials and Methods For this retrospective, single-center study (January 2021 to August 2023), patients with cT1-3N0M0 prostate cancer who underwent MRI and were treated with RT or RP were identified. Patients who underwent RT were randomly divided into cross-validation and test RT groups. An AI segmentation algorithm was trained to delineate Prostate Imaging Reporting and Data System (PI-RADS) 3–5 lesions in the cross-validation RT group before providing segmentations for the test RT and RP groups. Cox regression models were used to evaluate the association between VAI and
Source: pubs.rsna.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 77Patient Preferences for First-Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma: An Application of Multidimensional Thresholding - 10 month(s) ago
The Patient – Patient-Centered Outcomes Research – Patient preferences have the potential to influence the development of new treatments for locally advanced/metastatic urothelial carcinoma…
Source: link.springer.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 32Mismatch repair deficiency and microsatellite instability in urothelial carcinoma: a systematic review and meta-analysis - 11 month(s) ago
Background Mismatch repair deficiency (dMMR) and microsatellite instability-high (MSI-H) occur in a subset of cancers and have been shown to confer sensitivity to immune checkpoint inhibition (ICI); however, there is a lack of prospective data in urothelial carcinoma (UC).Methods and analysis We performed a systematic review to estimate the prevalence of dMMR and MSI-H in UC, including survival and clinical outcomes. We searched for studies published up to 26 October 2022 in major scientific databases. We screened 1745 studies and included 110. Meta-analyses were performed if the extracted data were suitable.Results The pooled weighted prevalences of dMMR in bladder cancer (BC) and upper tract UC (UTUC) were 2.30% (95% CI 1.12% to 4.65%) and 8.95% (95% CI 6.81% to 11.67%), respectively. The pooled weighted prevalences of MSI-H in BC and UTUC were 2.11% (95% CI 0.82% to 5.31%) and 8.36% (95% CI 5.50% to 12.53%), respectively. Comparing localised versus metastatic disease, the pooled wei
Source: bmjoncology.bmj.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1How I Practice: Role of Treatment Guidelines in Therapy Selection & Sequencing for mUC*Activity Post-Survey & Application for Credit* - 1 year(s) ago
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Source: www.surveymonkey.comCategories: General Medicine News, Hem/OncsTweet
Had so much fun (see interview https://t.co/j1cfke6UQd ) at the inaugural GU Early Thought Leaders 2025 Conference with @zklaassen where we met many future #GUOncology leaders! @PCFnews @urotoday with outstanding faculty @ERPlimackMD @montypal @ArjunBalarMD @AlanBryce9 @tbivala1 https://t.co/YO0q0fOKkA https://t.co/E8DZigvdex